Receptors, Estrogen

"Receptors, Estrogen" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Cytoplasmic proteins that bind estrogens and migrate to the nucleus where they regulate DNA transcription. Evaluation of the state of estrogen receptors in breast cancer patients has become clinically important.

Descriptor ID	D011960
MeSH Number(s)	D12.776.826.750.350 D12.776.930.778.350
Concept/Terms	Receptors, Estrogen Receptors, Estrogen Estrogen Receptors Receptors, Estrogen, Type II Receptors, Estrogen, Type II Estrogen Receptor Type II Estrogen Receptors Type II Estrogen Nuclear Receptor Estrogen Nuclear Receptor Nuclear Receptor, Estrogen Receptor, Estrogen Nuclear Receptors, Estrogen, Type I Receptors, Estrogen, Type I Estrogen Receptor Type I Estrogen Receptors Type I

Below are MeSH descriptors whose meaning is more general than "Receptors, Estrogen".

Chemicals and Drugs [D]
Amino Acids, Peptides, and Proteins [D12]
Proteins [D12.776]
Receptors, Cytoplasmic and Nuclear [D12.776.826]
Receptors, Steroid [D12.776.826.750]
Receptors, Estrogen [D12.776.826.750.350]
Transcription Factors [D12.776.930]
Receptors, Steroid [D12.776.930.778]
Receptors, Estrogen [D12.776.930.778.350]

Below are MeSH descriptors whose meaning is related to "Receptors, Estrogen".

Below are MeSH descriptors whose meaning is more specific than "Receptors, Estrogen".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Receptors, Estrogen" by people in this website by year, and whether "Receptors, Estrogen" was a major or minor topic of these publications.

Bar chart showing 37 publications over 21 distinct years, with a maximum of 3 publications in 1997 and 2005 and 2008 and 2011 and 2013 and 2018

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1996	1	0	1
1997	0	3	3
1998	0	1	1
2000	1	0	1
2001	1	1	2
2002	1	0	1
2004	0	1	1
2005	1	2	3
2007	0	2	2
2008	3	0	3
2009	0	1	1
2010	0	1	1
2011	1	2	3
2012	2	0	2
2013	1	2	3
2014	1	0	1
2015	0	2	2
2017	0	1	1
2018	2	1	3
2019	1	0	1
2020	0	1	1

Below are the most recent publications written about "Receptors, Estrogen" by people in Profiles.

Thomas A, Rhoads A, Suhl J, Conway KM, Hundley WG, McNally LR, Oleson J, Melin SA, Lynch CF, Romitti PA. Incidence and Survival by Human Epidermal Growth Factor Receptor 2 Status in Young Women With Stage I-III Breast Cancer: SEER, 2010-2016. Clin Breast Cancer. 2020 08; 20(4):e410-e422.

View in: PubMed
Lee KA, Shepherd ST, Johnston SR. Abemaciclib, a potent cyclin-dependent kinase 4 and 6 inhibitor, for treatment of ER-positive metastatic breast cancer. Future Oncol. 2019 Oct; 15(29):3309-3326.

View in: PubMed
Wellberg EA, Kabos P, Gillen AE, Jacobsen BM, Brechbuhl HM, Johnson SJ, Rudolph MC, Edgerton SM, Thor AD, Anderson SM, Elias A, Zhou XK, Iyengar NM, Morrow M, Falcone DJ, El-Hely O, Dannenberg AJ, Sartorius CA, MacLean PS. FGFR1 underlies obesity-associated progression of estrogen receptor-positive breast cancer after estrogen deprivation. JCI Insight. 2018 07 26; 3(14).

View in: PubMed
Ma Z, Kim YM, Howard EW, Feng X, Kosanke SD, Yang S, Jiang Y, Parris AB, Cao X, Li S, Yang X. DMBA promotes ErbB2-mediated carcinogenesis via ErbB2 and estrogen receptor pathway activation and genomic instability. Oncol Rep. 2018 Sep; 40(3):1632-1640.

View in: PubMed
Berger AC, Korkut A, Kanchi RS, Hegde AM, Lenoir W, Liu W, Liu Y, Fan H, Shen H, Ravikumar V, Rao A, Schultz A, Li X, Sumazin P, Williams C, Mestdagh P, Gunaratne PH, Yau C, Bowlby R, Robertson AG, Tiezzi DG, Wang C, Cherniack AD, Godwin AK, Kuderer NM, Rader JS, Zuna RE, Sood AK, Lazar AJ, Ojesina AI, Adebamowo C, Adebamowo SN, Baggerly KA, Chen TW, Chiu HS, Lefever S, Liu L, MacKenzie K, Orsulic S, Roszik J, Shelley CS, Song Q, Vellano CP, Wentzensen N, Weinstein JN, Mills GB, Levine DA, Akbani R. A Comprehensive Pan-Cancer Molecular Study of Gynecologic and Breast Cancers. Cancer Cell. 2018 04 09; 33(4):690-705.e9.

View in: PubMed
Farrugia DJ, Landmann A, Zhu L, Diego EJ, Johnson RR, Bonaventura M, Soran A, Dabbs DJ, Clark BZ, Puhalla SL, Jankowitz RC, Brufsky AM, Lembersky BC, Ahrendt GM, McAuliffe PF, Bhargava R. Magee Equation 3 predicts pathologic response to neoadjuvant systemic chemotherapy in estrogen receptor positive, HER2 negative/equivocal breast tumors. Mod Pathol. 2017 08; 30(8):1078-1085.

View in: PubMed
Bieniasz M, Radhakrishnan P, Faham N, De La O JP, Welm AL. Preclinical Efficacy of Ron Kinase Inhibitors Alone and in Combination with PI3K Inhibitors for Treatment of sfRon-Expressing Breast Cancer Patient-Derived Xenografts. Clin Cancer Res. 2015 Dec 15; 21(24):5588-600.

View in: PubMed
Kang SA, Hasan N, Mann AP, Zheng W, Zhao L, Morris L, Zhu W, Zhao YD, Suh KS, Dooley WC, Volk D, Gorenstein DG, Cristofanilli M, Rui H, Tanaka T. Blocking the adhesion cascade at the premetastatic niche for prevention of breast cancer metastasis. Mol Ther. 2015 Jun; 23(6):1044-1054.

View in: PubMed
Verma V, Sharma V, Singh V, Sharma S, Bishnoi AK, Chandra V, Maikhuri JP, Dwivedi A, Kumar A, Gupta G. Designed modulation of sex steroid signaling inhibits telomerase activity and proliferation of human prostate cancer cells. Toxicol Appl Pharmacol. 2014 Oct 15; 280(2):323-34.

View in: PubMed
Gunderson CC, Dutta S, Fader AN, Maniar KP, Nasseri-Nik N, Bristow RE, Diaz-Montes TP, Palermo R, Kurman RJ. Pathologic features associated with resolution of complex atypical hyperplasia and grade 1 endometrial adenocarcinoma after progestin therapy. Gynecol Oncol. 2014 Jan; 132(1):33-7.

View in: PubMed

People

Explore

Similar Concepts

Top Journals